GlassScriptPhysician profile
Susan Nunez
NPI 1295816817
$91,026.98
in general payments reported to CMS, 2019-2025
28 companies · $39K in 2025
The $39K reported for 2025 was more than what 96% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,701 · 2021: $1,136 · 2022: $1,902 · 2023: $9,248 · 2024: $24K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Travel and Lodging: $12K · Food and Beverage: $6,866 · Consulting Fee: $4,589 · Education: $50.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,043.38 |
| Travel and Lodging | $11,698.21 |
| Food and Beverage | $6,866.44 |
| Consulting Fee | $4,588.63 |
| Education | $50.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $38,246.20 | 2023-2025 | Crysvita |
| Abbvie INC. | $28,151.21 | 2019-2025 | |
| Novo Nordisk INC | $10,305.24 | 2019-2024 | Sogroya |
| Pfizer INC. | $6,965.65 | 2022-2025 | |
| Eton Pharmaceuticals, INC. | $2,952.44 | 2022-2025 | Alkindi, Increlex, Khindivi |
| Ascendis Pharma Endocrinology INC | $701.82 | 2022-2024 | |
| Dexcom, INC. | $591.20 | 2020-2024 | Dexcom G6 Transmitter |
| Agios Pharmaceuticals, INC. | $555.00 | 2019 | |
| Tandem Diabetes Care, INC. | $429.08 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $344.50 | 2021-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Tolmar, INC. | $331.03 | 2023-2025 | Fensolvi |
| Sanofi-Aventis U.S. LLC | $236.23 | 2023-2024 | |
| Ultragenyx Pharmaceutical INC. | $231.35 | 2019-2023 | |
| Beta Bionics, INC. | $193.17 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Insulet Corporation | $153.00 | 2019-2024 | Omnipod |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $151.31 | 2025 | Twiist |
| Endo USA, INC. | $103.15 | 2024 | Supprelin |
| Lilly USA, LLC | $91.05 | 2019 | |
| Abbott Laboratories | $60.14 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $38.50 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $36.64 | 2025 | Uzedy |
| Ibsa Pharma INC. | $34.70 | 2023-2024 | Tirosint, Tirosint, Licart |
| Xeris Pharmaceuticals, INC. | $34.09 | 2021-2024 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $23.59 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $17.88 | 2023 | Imcivree |
| Azurity Pharmaceuticals, INC. | $17.23 | 2024 | Triptodur |
| Novartis Pharmaceuticals Corporation | $16.98 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $14.60 | 2023 | Baqsimi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Nunez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.